MedTrace Logo

Pharmacokinetics of ZSP1273 in Participants With Hepatic Impairment

NCT05856513 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2023-12-01

No results posted yet for this study

Summary

This study will assess the effect of hepatic impairment on the pharmacokinetics (PK), safety and tolerability of ZSP1273.

Conditions

  • Hepatic Impairment
  • Pharmacokinetics

Interventions

DRUG

ZSP1273

Participants receive ZSP1273 orally.

DRUG

ZSP1273

Participants receive ZSP1273 orally.

DRUG

ZSP1273

Participants receive ZSP1273 orally.

Sponsors & Collaborators

  • Guangdong Raynovent Biotech Co., Ltd

    lead INDUSTRY

Study Design

Allocation
NON_RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
68 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-06-15
Primary Completion
2023-07-04
Completion
2023-07-04

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05856513 on ClinicalTrials.gov